Axonics (Nasdaq:AXNX) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

AXNX Overzicht aandelen

Axonics, Inc. is een medisch technologiebedrijf dat zich bezighoudt met de ontwikkeling en commercialisering van nieuwe producten voor de behandeling van blaas- en darmstoornissen.

Over het bedrijf

AXNX fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	4/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Verhandeld tegen 65.1% onder onze schatting van de reële waarde

De winst zal naar verwachting met 50.44% per jaar groeien

De winst is de afgelopen 5 jaar met 21.7% per jaar gegroeid

Risicoanalyse

Geen risico's gedetecteerd voor AXNX uit onze risicocontroles.

Axonics, Inc. Concurrenten

Inari Medical

NasdaqGS:NARI

US$2.4b

QuidelOrtho

NasdaqGS:QDEL

US$2.9b

Integer Holdings

NYSE:ITGR

US$4.3b

PROCEPT BioRobotics

NasdaqGM:PRCT

US$3.8b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Axonics
Historische aandelenkoersen
Huidige aandelenkoers	US$69.63
52 Week Hoogtepunt	US$69.91
52 Week Laag	US$48.30
Bèta	0.82
11 maand verandering	1.16%
3 maanden verandering	3.17%
1 Jaar Verandering	19.72%
33 jaar verandering	10.24%
5 jaar verandering	244.62%
Verandering sinds IPO	364.82%

Recent nieuws en updates

Recent updates

A Look At The Fair Value Of Axonics, Inc. (NASDAQ:AXNX)

Jul 14

Axonics, Inc.'s (NASDAQ:AXNX) Earnings Haven't Escaped The Attention Of Investors

Jun 20

Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 21% Discount?

Mar 27

Here's Why We're Not At All Concerned With Axonics' (NASDAQ:AXNX) Cash Burn Situation

Feb 28

Axonics: A Strong Medical Device Play With Significant Revenue Growth Opportunities

May 30

Axonics (NASDAQ:AXNX) Is In A Strong Position To Grow Its Business

Apr 19

We're Hopeful That Axonics (NASDAQ:AXNX) Will Use Its Cash Wisely

Sep 15

Rendement voor aandeelhouders

	AXNX	US Medical Equipment	US Markt
7D	0.04%	-1.2%	0.1%
1Y	19.7%	20.7%	32.2%

Rendement versus industrie: AXNX kwam overeen met de US Medical Equipment industrie, die het afgelopen jaar een rendement opleverde van 20.7 %.

Rendement versus markt: AXNX presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 34.1 % opleverde.

Prijsvolatiliteit

Is AXNX's price volatile compared to industry and market?
AXNX volatility
AXNX Average Weekly Movement	0.5%
Medical Equipment Industry Average Movement	8.5%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: AXNX heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 1% ) van AXNX is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2012	797	Ray Cohen	www.axonics.com

Axonics, Inc. is een medisch technologiebedrijf dat zich bezighoudt met de ontwikkeling en commercialisering van nieuwe producten voor de behandeling van blaas- en darmstoornissen. De systemen voor sacrale neuromodulatie (SNM) worden gebruikt voor de behandeling van patiënten met een overactieve blaas (OAB), waaronder urinaire aandrangincontinentie en urinaire aandrangfrequentie, evenals ontlastingsincontinentie (FI) en niet-obstructieve urineretentie (UR); en oplaadbare (R20) en oplaadvrije (F15) implanteerbare SNM-systemen die milde elektrische pulsen afgeven aan de betreffende sacrale zenuw om de normale communicatie van en naar de hersenen te herstellen en zo de symptomen van OAB, UR en FI te verminderen. Het bedrijf biedt ook Bulkamid aan, een urethraal vulmiddel voor de behandeling van urine-incontinentie bij vrouwen.

Axonics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Axonics zich tot de beurswaarde?
AXNX fundamentele statistieken
Marktkapitalisatie	US$3.56b
Inkomsten(TTM)	-US$1.71m
Inkomsten(TTM)	US$408.81m

8.7x

P/S-verhouding

-2,080x

Koers/Winstverhouding

Is AXNX overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
AXNX resultatenrekening (TTM)
Inkomsten	US$408.81m
Kosten van inkomsten	US$98.55m
Brutowinst	US$310.26m
Overige uitgaven	US$311.97m
Inkomsten	-US$1.71m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.033
Brutomarge	75.89%
Nettowinstmarge	-0.42%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde AXNX op de lange termijn?

Bekijk historische prestaties en vergelijking

AXNX Overzicht aandelen

Beloningen

Risicoanalyse

Axonics, Inc. Concurrenten

NasdaqGS:NARI

US$2.4b

NasdaqGS:QDEL

US$2.9b

NYSE:ITGR

US$4.3b

NasdaqGM:PRCT

US$3.8b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Axonics, Inc. Prevails in Patent Infringement Lawsuit with Medtronic

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

CEO & Director exercised options to buy US$7.1m worth of stock.

Forecast breakeven date moved forward to 2024

Axonics, Inc. Receives Regulatory Approval for Recharge-Free SNM System in Australia

Forecast breakeven date pushed back to 2025

Recent updates

Axonics, Inc. Prevails in Patent Infringement Lawsuit with Medtronic

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

CEO & Director exercised options to buy US$7.1m worth of stock.

Forecast breakeven date moved forward to 2024

Axonics, Inc. Receives Regulatory Approval for Recharge-Free SNM System in Australia

Forecast breakeven date pushed back to 2025

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Shareholder dilution

Medtronic Files Itc Action Against Axonics to Stop Unauthorized Use of Medtronic Innovations

Full year 2023 earnings: EPS exceeds analyst expectations

Chief Commercial Officer exercised options and sold US$1.1m worth of stock

Insufficient new directors

BBoston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders for $3.6 billion.

BBoston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders for $3.6 billion.

Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) for $3.7 billion.

Chief Medical Officer notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Axonics, Inc. Updates Revenue Guidance for the Fiscal Year 2023

Axonics, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Axonics, Inc. Announces Chief Financial Officer Changes

Chief Commercial Officer notifies of intention to sell stock

Forecast breakeven date moved forward to 2024

Axonics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

A Look At The Fair Value Of Axonics, Inc. (NASDAQ:AXNX)

Axonics, Inc.'s (NASDAQ:AXNX) Earnings Haven't Escaped The Attention Of Investors

Consensus estimates of losses per share improve by 37%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

President & CFO notifies of intention to sell stock

Now 20% undervalued after recent price drop

Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 21% Discount?

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Full year 2022 earnings: EPS exceeds analyst expectations

Here's Why We're Not At All Concerned With Axonics' (NASDAQ:AXNX) Cash Burn Situation

Chief Operating Officer notifies of intention to sell stock

Now 21% undervalued after recent price drop

Executive VP exercised options and sold US$705k worth of stock

Axonics Receives FDA Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

Chief Commercial Officer exercised options and sold US$1.9m worth of stock

Axonics, Inc. Provides Revenue Guidance for 2023

Forecast to breakeven in 2025

Axonics, Inc. to Report Fiscal Year 2022 Results on Jan 11, 2023

Independent Director recently sold US$135k worth of stock

Axonics, Inc. Receives Health Canada Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 32% Discount?

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Axonics, Inc. Updates Revenue Guidance for the Year 2022

Axonics, Inc. to Report Q3, 2022 Results on Oct 31, 2022

Axonics stock falls 5.6% after Needham downgrades rating

Chief Technology Officer notifies of intention to sell stock

Executive VP exercised options and sold US$551k worth of stock

Chief Medical Officer recently sold US$748k worth of stock

Axonics Announces First Patient Implants in Canada with New Recharge-Free Sacral Neuromodulation System

Axonics Stock Is A Buy Amid Current Capex Cycle

Executive VP notifies of intention to sell stock

Chief Operating Officer notifies of intention to sell stock

Consensus estimates of losses per share improve by 13%

Axonics prices stock offering of 1.75M shares